Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
328 GBX | -1.50% |
|
-11.35% | -6.95% |
06-11 | MaxCyte CEO Maher Masoud buys 100,000 shares | AN |
06-11 | Maxcyte Insider Bought Shares Worth $489,066, According to a Recent SEC Filing | MT |
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.95% | 442M | C+ | ||
+4.85% | 216B | B | ||
+9.86% | 190B | B- | ||
+31.11% | 152B | B- | ||
+34.08% | 113B | A- | ||
+1.90% | 64.04B | A- | ||
+19.45% | 54.34B | B+ | ||
+1.63% | 49.21B | B+ | ||
-3.12% | 39.41B | A | ||
+1.93% | 35.99B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MXCT Stock
- Ratings MaxCyte, Inc.